What Is ARA-290? Definition and What Research Reports

Plain definition

ARA-290 (also written ARA 290, and known by the non-proprietary name cibinetide) is a laboratory-made peptide — a very short chain of 11 amino acids — whose sequence was copied from one exposed face of the natural hormone erythropoietin (EPO). EPO is best known for telling bone marrow to make red blood cells, but researchers have also described a separate, tissue-protective signalling role for it. ARA-290 was designed to keep that second role while leaving out the blood-forming one, which is why it is repeatedly labelled non-erythropoietic or nonhematopoietic in the literature. In practice, when someone writes "ARA-290" they are referring to an investigational peptide studied mainly in the context of nerve fibre damage, neuropathic pain and inflammation — not to an approved medicine. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or treatment decision.

What ARA-290 is in biochemical terms

ARA-290 is a linear 11-residue peptide derived from helix B of erythropoietin, and for that reason it is sometimes called a helix B surface peptide (pHBSP). Because the fragment comes from the part of EPO that faces away from the classical erythropoietin receptor homodimer, it does not engage that receptor in the way the full hormone does. Papers describing the peptide consistently characterise it as engineered from the tertiary structure of erythropoietin while lacking erythropoietic activity, a framing used in both preclinical pain work (PMID 24529189) and in cell-based toxicology work (PMID 32335150).

The receptor complex

The receptor most often named in ARA-290 research is a heteromeric complex of the erythropoietin receptor (EPOR) and the beta-common receptor (βcR, CD131), frequently referred to in the literature as the "innate repair receptor." A 2018 study in mice with genetic diabetes described wound-healing effects in terms of activation of the EPOR–β common receptor complex by cibinetide (PMID 29223734). Downstream, investigators have reported effects on innate immune cells: cibinetide dampened innate immune cell functions in an experimental colitis model (PMID 29026145), and ARA 290 inhibited macrophage activation in a transplanted-islet model (PMID 26683514).

How the term is used in peptide research

Across published work the term appears in a few consistent contexts:

• As a non-erythropoietic EPO analogue. Authors use ARA-290 as a tool to separate EPO's tissue-protective signalling from its effect on red blood cells.
• As a probe of neuro-immune interaction. A 2016 paper examined ARA 290 and pathophysiological pain with reference to the TRPV1 channel, framing the work as integration between the immune system and nociception (PMID 26774587).
• As a clinical investigational agent for small fiber neuropathy. This is the setting in which the peptide has been most discussed in humans, including a review of ARA 290 for small fiber neuropathy in sarcoidosis (PMID 24555851).
• As a targeting moiety in imaging chemistry. Researchers synthesised and evaluated a ^99mTc-DOTA-ARA-290 conjugate as a potential SPECT tracer for targeting cardiac ischemic regions (PMID 35317117).

Naming conventions

"ARA 290" (with a space), "ARA-290" and "ARA290" all appear in titles of indexed papers, alongside "cibinetide." Searching only one spelling will miss part of the literature — the colitis and wound-healing studies, for example, are indexed under cibinetide (PMID 29026145, PMID 29223734).

Where the term is misused

Several recurring errors show up in non-scientific writing about this peptide:

• Treating it as a form of EPO. ARA-290 shares a sequence fragment with erythropoietin but is repeatedly described in study titles as nonhematopoietic or non-erythropoietic (PMID 26683514, PMID 32335150). Assuming it behaves like EPO on red cell mass misreads the design intent of the molecule.
• Generalising from animal or cell models to people. Findings such as attenuation of doxorubicin-induced genotoxicity and oxidative stress were reported in an in vitro system (PMID 32335150), and improved wound healing was reported in mice with genetic diabetes (PMID 29223734). These are not human clinical outcomes.
• Calling it an approved drug. The human data that exist are described by their own authors as pilot or exploratory work — for example a randomized, double-blind pilot study in sarcoidosis patients with symptoms of small fiber neuropathy (PMID 23168581). Investigational status is not the same as regulatory approval.
• Confusing "anti-inflammatory" with immunosuppression. The published framing is modulation of innate immune cell activity — monocytes, macrophages, microglia — rather than broad immune shutdown (PMID 34343617).

Related terms

What the published literature reports

Human studies

A randomized, double-blind pilot study assessed the safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy; the study used intravenous administration over a short course of weeks and reported on both tolerability and symptom outcomes (PMID 23168581). A related report in patients with sarcoidosis-associated small nerve fiber loss described improvement in symptoms together with an increase in corneal nerve fiber density measured by corneal imaging (PMID 24136731). In a separate population, researchers reported that ARA 290 improved metabolic control and neuropathic symptoms in patients with type 2 diabetes (PMID 25387363). A 2014 expert review summarised the state of this evidence for small fiber neuropathy in sarcoidosis (PMID 24555851).

Animal and cell models

In rodent pain research, one study reported long-term relief of neuropathic pain coupled with suppression of the spinal microglia response (PMID 24529189), while another attributed relief of pathophysiological pain to effects involving the TRPV1 channel (PMID 26774587). In transplantation work, ARA 290 inhibited macrophage activation and prevented damage to transplanted islets (PMID 26683514). In a neurodegeneration model, early monocyte modulation by the peptide was reported to decelerate Alzheimer's-like pathology progression (PMID 34343617). Gastrointestinal and dermal models added colitis (PMID 29026145) and impaired diabetic wound healing (PMID 29223734) to the list of contexts examined.

Safety and Adverse Events: What Studies Report

Formal human safety information about this peptide is limited to small trials. The randomized, double-blind pilot study in sarcoidosis patients was explicitly designed around safety as well as efficacy endpoints, and the authors framed their findings in those terms (PMID 23168581). The 2014 review of ARA 290 for small fiber neuropathy in sarcoidosis likewise discussed the investigational profile of the peptide rather than an established safety record (PMID 24555851). The type 2 diabetes study reported metabolic and symptom outcomes in a similarly small clinical population (PMID 25387363). Because the published human sample sizes are small and follow-up periods short, the literature does not support conclusions about uncommon or long-term adverse events.

Limits of the current evidence

1. Most mechanistic findings come from rodent and cell systems, not humans.
2. Human studies to date have been pilot-scale and concentrated in two populations: sarcoidosis-associated small fiber neuropathy and type 2 diabetes.
3. Outcome measures differ between studies — symptom questionnaires, corneal nerve fiber density, metabolic markers — which makes cross-study comparison difficult.
4. Imaging chemistry work using a ^99mTc-DOTA-ARA-290 conjugate is a separate research use of the sequence and says nothing about therapeutic effect (PMID 35317117).

Readers comparing summaries of ARA-290 should check whether a claim traces back to a human trial, an animal model or a cell culture experiment, since the three appear side by side in popular write-ups of this peptide.

References

• Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study (Molecular Medicine, 2012)
• ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density (Molecular Medicine, 2013)
• ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response (Molecular Pain, 2014)
• ARA 290 for treatment of small fiber neuropathy in sarcoidosis (Expert Opinion on Investigational Drugs, 2014)
• ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes (Molecular Medicine, 2015)
• A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets (Transplantation, 2016)
• ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception (Peptides, 2016)
• Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis (Scientific Reports, 2017)
• Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes (BBA Molecular Basis of Disease, 2018)
• An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress (Toxicology in Vitro, 2020)
• Synthesis and evaluation of 99mTc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region (Iranian Journal of Basic Medical Sciences, 2021)
• Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression (Brain, Behavior, and Immunity, 2022)